KOD · Transaction Nov 8, 2022 · Filed Dec 12, 2022 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · KOD
+1.19% · +$0.3900 · Vol Not reported
Pre-market · updated 07:20:07 ET
Kodiak Sciences Inc
Biotechnology
$33.10
Follow $KOD
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $KOD by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredFri Sep 18 · last completed session · Pre-market · regular session opens 9:30 ET · KOD
MethodologyKOD
Kodiak Sciences Inc
Fri Sep 18 · last completed session · Pre-market · regular session opens 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
45/ 100
Veridion Score
Middle range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Fri Sep 18 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is KOD moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Kodiak Sciences Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
2018
Employees
124
Country
US
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$32.71
Last session
Day high
$32.71
Last session
Day low
$32.71
Last session
Previous close
$32.71
52W high
$46.44
-28.73% from high
52W low
$11.60
62% of range
Market cap
$2.1B
EPS
$-4.2400
Beta
1.01
Shares out
62.8M
Avg volume
641.6K
VWAP
$32.71
Last session
Price history computed in-house
1W
-0.12%
1M
-13.64%
3M
-10.66%
1Y
+247.32%
YTD
+18.38%
SMA 50 $39.37 · below
SMA 200 $33.67 · below
52W position 62%
KOD overview
Related filings and maps
Public disclosures
Congress activity in KOD
Official filing ↗
Chris JacobsSell
Kodiak Sciences Inc · Transaction Nov 8, 2022 · Filed Dec 12, 2022 · $1,001 to $15,000
KOD · Transaction Jul 18, 2022 · Filed Sep 9, 2022 · $1,001 to $15,000
Chris JacobsBuy
Kodiak Sciences Inc · Transaction Jul 18, 2022 · Filed Sep 9, 2022 · $1,001 to $15,000
Federal contracts
KOD contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KOD in this window.
Lobbying spend
KOD lobbying filings, year to date.
Registered lobbying filings matched to Kodiak Sciences Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KOD in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for KOD.
Options
Sovereign unlock shows live options positioning for KOD.